MX2012006622A - Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas. - Google Patents

Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas.

Info

Publication number
MX2012006622A
MX2012006622A MX2012006622A MX2012006622A MX2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A MX 2012006622 A MX2012006622 A MX 2012006622A
Authority
MX
Mexico
Prior art keywords
compositions
methods
prostglandin
aqueous compositions
stable aqueous
Prior art date
Application number
MX2012006622A
Other languages
English (en)
Spanish (es)
Inventor
Robert M Burk
Wha Bin Im
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43503864&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012006622(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2012006622A publication Critical patent/MX2012006622A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2012006622A 2009-12-09 2010-11-05 Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas. MX2012006622A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26789709P 2009-12-09 2009-12-09
PCT/US2010/055590 WO2011071620A1 (en) 2009-12-09 2010-11-05 Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof

Publications (1)

Publication Number Publication Date
MX2012006622A true MX2012006622A (es) 2012-08-15

Family

ID=43503864

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012006622A MX2012006622A (es) 2009-12-09 2010-11-05 Composiciones acuosas estables de profarmacos de agonista de prostaglandina y metodos para el uso de estas.

Country Status (16)

Country Link
US (2) US20110136872A1 (enExample)
EP (1) EP2509582A1 (enExample)
JP (2) JP5955774B2 (enExample)
KR (1) KR20120106788A (enExample)
CN (1) CN102762195B (enExample)
AR (1) AR078929A1 (enExample)
AU (1) AU2010328555B2 (enExample)
CA (1) CA2783707A1 (enExample)
CL (1) CL2012001545A1 (enExample)
IL (1) IL220240A0 (enExample)
MX (1) MX2012006622A (enExample)
NZ (1) NZ600577A (enExample)
RU (1) RU2012127869A (enExample)
SG (1) SG181600A1 (enExample)
TW (1) TW201138766A (enExample)
WO (1) WO2011071620A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6270848B2 (ja) 2012-08-27 2018-01-31 アラーガン、インコーポレイテッドAllergan,Incorporated ベータ−クロロシクロペンタンの親水性エステルプロドラッグの使用による角膜中央部肥厚の低下
KR101535825B1 (ko) 2012-09-25 2015-07-10 엘지디스플레이 주식회사 표시장치 및 이의 라인결함 검출방법
WO2015175075A1 (en) * 2014-02-20 2015-11-19 Allergan, Inc. Reduced central corneal thickening by use of hydrophilic ester prodrugs of beta-chlorocyclopentanes
ES2757798T3 (es) 2014-10-02 2020-04-30 Allergan Inc Profármacos de éster de gamma-lactamas y su uso

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5034413A (en) 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
WO2000004898A1 (en) * 1998-07-21 2000-02-03 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
PT1321144E (pt) * 2000-09-13 2011-03-10 Santen Pharmaceutical Co Ltd Colírio
EP1532981B1 (en) * 2002-08-23 2007-09-26 Santen Pharmaceutical Co., Ltd. Stable eye drops containing latanoprost as the active ingredient
ES2320770T3 (es) * 2004-05-26 2009-05-28 Arturo Jimenez Bayardo Metodo de preparacion de una solucion oftalmica de latanoprost y la solucion asi producida.
US20050276867A1 (en) * 2004-06-09 2005-12-15 Allergan, Inc. Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative
EP1856042B1 (en) * 2005-03-10 2012-06-27 Allergan, Inc. Substituted gamma lactams as therapeutic agents
EP2123278B1 (en) * 2007-02-07 2013-01-09 Teika Pharmaceutical Co., Ltd. Eye drop preparation comprising latanoprost
US7820661B2 (en) * 2008-04-24 2010-10-26 Allergan, Inc. Substituted gamma lactams as therapeutics agents
EP2127638A1 (en) * 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma

Also Published As

Publication number Publication date
JP5955774B2 (ja) 2016-07-20
AR078929A1 (es) 2011-12-14
CL2012001545A1 (es) 2012-08-31
IL220240A0 (en) 2012-07-31
KR20120106788A (ko) 2012-09-26
WO2011071620A1 (en) 2011-06-16
CN102762195B (zh) 2016-05-18
US20110136872A1 (en) 2011-06-09
NZ600577A (en) 2014-10-31
JP2013513606A (ja) 2013-04-22
SG181600A1 (en) 2012-07-30
TW201138766A (en) 2011-11-16
AU2010328555A1 (en) 2012-07-05
JP2016056207A (ja) 2016-04-21
RU2012127869A (ru) 2014-01-20
CN102762195A (zh) 2012-10-31
EP2509582A1 (en) 2012-10-17
CA2783707A1 (en) 2011-06-16
AU2010328555B2 (en) 2016-05-26
US20160220677A1 (en) 2016-08-04

Similar Documents

Publication Publication Date Title
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2011058474A8 (en) N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
CA2711696C (en) Therapeutic compositions for treatment of ocular inflammatory disorders
WO2010018113A3 (en) Bi-aryl aminotetralines
TW200801000A (en) Spiroindolinone derivatives
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
WO2009074950A3 (en) Thiophene derivatives as agonists of s1p1/edg1
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
MY162167A (en) Substituted acetyl-coa carboxylase inhibitors
WO2010018109A3 (en) Substituted aminotetralines
MY183312A (en) Pharmaceutical formulation
PH12014501937B1 (en) Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
HK1202415A1 (en) Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of use thereof
WO2012138713A3 (en) Multifunctional radical quenchers for the treatment of mitochondrial dysfunction
WO2010018112A3 (en) Monoaryl aminotetralines
UA116894C2 (uk) Похідні піразину як агоністи канабіноїдного рецептора 2
PT1753723E (pt) Derivados de quinolina substituída como inibidores de quinesina mitótica
EP2328550A4 (en) MUKOADHÄRENTE COMPOSITIONS AND ITS USE
WO2011151436A3 (en) Azepin-derivatives as derivatives as g- protein coupled receptor (gpr43) agonists
TW200800951A (en) Substituted imidazole compounds as KSP inhibitors
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
PH12013500545A1 (en) Oxadiazole inhibitors of leukotriene production
NZ600577A (en) Stable aqueous compositions of prostglandin agonist prodrugs and methods for use thereof
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal